Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia - PubMed
3 hours ago
- #acute myeloid leukemia
- #CAR-NK cells
- #mRNA-LNP
- Engineering CLL-1 CAR-NK cells using mRNA-LNP for enhanced antitumor activity in acute myeloid leukemia (AML).
- Reversal of HLA-E-mediated resistance in AML through engineered CAR-NK cells.
- Ethical approvals obtained from Ruijin Hospital Ethics Committee and Institutional Animal Care and Use Committee (IACUC).
- No competing interests declared by the authors.
- References include recent studies on AML diagnosis, management, and treatment combinations like Venetoclax plus Azacitidine.